Head and neck cancer cells are efficiently infected by AD5/35 hybrid virus

Journal of Gene Medicine

Volumn 8, Issue 10, 2006, Pages 1223-1231

  Suominen, Elina ^a,b   Toivonen, Raine ^a,b   Grenman, Reidar ^b   Savontaus, Mikko ^a,b  

^a ÅBO AKADEMI UNIVERSITY   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Adenovirus; Cancer treatment; Gene therapy; Targeting

Indexed keywords

BETA GALACTOSIDASE; CD51 ANTIGEN; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; MEMBRANE COFACTOR RECEPTOR PROTEIN; UNCLASSIFIED DRUG;

ADENOVIRUS 5; ADENOVIRUS VECTOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CELL STRAIN HEK293; COMPARATIVE STUDY; CONTROLLED STUDY; FLOW CYTOMETRY; GENE EXPRESSION; GENE EXPRESSION SYSTEM; GENE TARGETING; GENETIC TRANSDUCTION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; SQUAMOUS CELL CARCINOMA; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS DNA CELL DNA INTERACTION; VIRUS HYBRID; VIRUS INFECTION;

ADENOVIRIDAE; ANIMALS; CARCINOMA, SQUAMOUS CELL; CELLS, CULTURED; DISEASE MODELS, ANIMAL; GENE THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MICE; MICE, SCID; RECEPTORS, VIRUS; TRANSDUCTION, GENETIC; TRANSGENES; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; VIRUS ATTACHMENT;

ADENOVIRIDAE; COXSACKIEVIRUS;

EID: 33750505898     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.957     Document Type: Article

References (44)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Vokes EE, Weichselbaum RR, Lippman SM, et al. Head and neck cancer. N Engl J Med 1993; 328: 184-194.
3. van Dongen GA, Snow GB. Prospects for future studies in head and neck cancer. Eur J Surg Oncol 1997; 23: 486-491.
4. Goebel EA, Davidson BL, Zabner J, et al. Adenovirus-mediated gene therapy for head and neck squamous cell carcinomas. Ann Otol Rhinol Laryngol 1996; 105: 562-567.
5. Blackwell JL, Miller CR, Douglas JT, et al. Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1999; 125: 856-863.
6. Liu TJ, Zhang WW, Taylor DL, et al. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res 1994; 54: 3662-3667.
7. Clayman GL, el-Naggar AK, Roth JA, et al. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 1995; 55: 1-6.
8. Hanna NN, Mauceri HJ, Wayne JD, et al. Virally directed cytosine deaminase/5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts. Cancer Res 1997; 57: 4205-4209.
9. Chia MC, Shi W, Li JH, et al. A conditionally replicating adenovirus for nasopharyngeal carcinoma gene therapy. Mol Ther 2004; 9: 804-817.
10. Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997; 275: 1320-1323.
11. Tomko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci USA 1997; 94: 3352-3356.
12. Roelvink PW, Lizonova A, Lee JG, et al. The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J Virol 1998; 72: 7909-7915.
13. Wickham TJ, Mathias P, Cheresh DA, et al. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993; 73: 309-319.
14. Li D, Duan L, Freimuth P, et al. Variability of adenovirus receptor density influences gene transfer efficiency and therapeutic response in head and neck cancer. Clin Cancer Res 1999; 5: 4175-4181.
15. Hemmi S, Geertsen R, Mezzacasa A, et al. The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Hum Gene Ther 1998; 9: 2363-2373.
16. Wickham TJ, Segal DM, Roelvink PW, et al. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J Virol 1996; 70: 6831-6838.
17. Nettelbeck DM, Miller DW, Jerome V, et al. Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105). Mol Ther 2001; 3: 882-891.
18. Kasono K, Blackwell JL, Douglas JT, et al. Selective gene delivery to head and neck cancer cells via an integrin targeted adenoviral vector. Clin Cancer Res 1999; 5: 2571-2579.
19. Einfeld DA, Schroeder R, Roelvink PW, et al. Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J Virol 2001; 75: 11284-11291.
20. Gaggar A, Shayakhmetov DM, Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat Med 2003; 9: 1408-1412.
21. Stevenson SC, Rollence M, Marshall-Neff J, et al. Selective targeting of human cells by a chimeric adenovirus vector containing a modified fiber protein. J Virol 1997; 71: 4782-4790.
22. Gall J, Kass-Eisler A, Leinwand L, et al. Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. J Virol 1996; 70: 2116-2123.
23. Havenga MJ, Lemckert AA, Grimbergen JM, et al. Improved adenovirus vectors for infection of cardiovascular tissues. J Virol 2001; 75: 3335-3342.
24. Goossens PH, Havenga MJ, Pieterman E, et al. Infection efficiency of type 5 adenoviral vectors in synovial tissue can be enhanced with a type 16 fiber. Arthritis Rheum 2001; 44: 570-577.
25. Shayakhmetov DM, Papayannopoulou T, Stamatoyannopoulos G, et al. Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J Virol 2000; 74: 2567-2583.
26. Mizuguchi H, Hayakawa T. Adenovirus vectors containing chimeric type 5 and type 35 fiber proteins exhibit altered and expanded tropism and increase the size limit of foreign genes. Gene 2002; 285: 69-77.
27. Shinozaki K, Suominen E, Carrick F, et al. Efficient infection of tumor endothelial cells by a capsid-modified adenovirus. Gene Ther 2006; 13: 52-59.
28. Seya T, Hirano A, Matsumoto M, et al. Human membrane cofactor protein (MCP, CD46): multiple isoforms and functions. Int J Biochem Cell Biol 1999; 31: 1255-1260.
29. Santoro F, Kennedy PE, Locatelli G, et al. CD46 is a cellular receptor for human herpesvirus 6. Cell 1999; 99: 817-827.
30. Dorig RE, Marcil A, Chopra A, et al. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 1993; 75: 295-305.
31. Grenman SE, Van Dyke DL, Worsham MJ, et al. Phenotypic characterization, karyotype analysis and in vitro tamoxifen sensitivity of new ER-negative vulvar carcinoma cell lines, UM-SCV-1A and UM-SCV-1B. Int J Cancer 1990; 45: 920-927.
32. Bautista DS, Hitt M, McGrory J, et al. Isolation and characterization of insertion mutants in E1A of adenovirus type 5. Virology 1991; 182: 578-596.
33. Witlox MA, Van Beusechem VW, Grill J, et al. Epidermal growth factor receptor targeting enhances adenoviral vector based suicide gene therapy of osteosarcoma. J Gene Med 2002; 4: 510-516.
34. Zeimet AG, Muller-Holzner E, Schuler A, et al. Determination of molecules regulating gene delivery using adenoviral vectors in ovarian carcinomas. Gene Ther 2002; 9: 1093-1100.
35. Matsumoto K, Shariat SF, Ayala GE, et al. Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer. Urology 2005; 66: 441-446.
36. Martin TA, Watkins G, Jiang WG. The coxsackie-adenovirus receptor has elevated expression in human breast cancer. Clin Exp Med 2005; 5: 122-128.
37. Okegawa T, Pong RC, Li Y, et al. The mechanism of the growth-inhibitory effect of coxsackie and adenovirus receptor (CAR) on human bladder cancer: a functional analysis of car protein structure. Cancer Res 2001; 61: 6592-6600.
38. Simpson KL, Jones A, Norman S, et al. Expression of the complement regulatory proteins decay accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46) and CD59 in the normal human uterine cervix and in premalignant and malignant cervical disease. Am J Pathol 1997; 151: 1455-1467.
39. Varsano S, Rashkovsky L, Shapiro H, et al. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance. Clin Exp Immunol 1998; 113: 173-182.
40. Dechecchi MC, Melotti P, Bonizzato A, et al. Heparan sulfate glycosaminoglycans are receptors sufficient to mediate the initial binding of adenovirus types 2 and 5. J Virol 2001; 75: 8772-8780.
41. Available: www.wiley.co.uk/genmed/clinical/.
42. Douglas JT, Kim M, Sumerel LA, et al. Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors. Cancer Res 2001; 61: 813-817.
43. Khuri FR, Nemunaitis J, Ganly I, et al. a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879-885.
44. Sova P, Ren XW, Ni S, et al. A tumor-targeted and conditionally replicating oncolytic adenovirus vector expressing TRAIL for treatment of liver metastases. Mol Ther 2004; 9: 496-509.